Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Richard Kelly

Nuclear Radiology Augusta, GA Medical Doctor

NPI 1508820424 CMS profile 975715

840 Stevens Creek Rd, Augusta, GA 30907

Open in the dashboard

General payments

$360

25 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Richard Kelly of Augusta, GA is reported in the CMS Open Payments database as having received $360 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 57th percentile of Nuclear Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $12 1
2020 General $97 6
2019 General $251 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Kelly
  • Nuclear Radiology median
  • Middle half of Nuclear Radiology
  • National median

In program year 2025, general payments to Richard Kelly were reported at $0. Among 103 Nuclear Radiology profiles paid that year, the median was $145 and the middle half received between $47 and $1,684.

Show as a table
Year Richard Kelly Nuclear Radiology median Middle half National median
2019 $251 $136 $49–$543 $163
2020 $97 $102 $32–$2,014 $114
2021 $12 $72 $25–$381 $132
2022 $0 $69 $25–$202 $149
2023 $0 $89 $28–$281 $160
2024 $0 $133 $40–$829 $164
2025 $0 $145 $47–$1,684 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Janssen Biotech, Inc. $316 22 payments
  2. Eisai Inc. $29 2 payments
  3. Boston Scientific Corporation $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $360 25 payments
Products named General payments · program years 2019–2021
  1. DARZALEX $276 19 payments
  2. IMBRUVICA $242 16 payments
  3. ERLEADA $74 6 payments
  4. Halaven $16 1 payment
  5. SPECTRA WAVEWRITER $15 1 payment
  6. Lenvima $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$29,086

Medicare's payments for the services billed

Medicare patients

491

Average age 73

Services billed

625

268 women, 223 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 28%
Depression 26%
Chronic kidney disease 23%
COPD 19%
Atrial fibrillation 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nuclear Radiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record